Molecular hydrogen as a potential treatment of chronic rejection after experimental lung transplantation
Molecular hydrogen as a potential treatment of chronic rejection after experimental lung transplantation
批准号:
358674784
负责人:
Professor Dr. Stephan Hirt, since 5/2018
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2017
资助国家:
德国
项目状态:
已结题
起止时间:
2016-12-31 至 2022-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Lung transplantation (LTx) has become an effective clinical treatment for patients with end-stage pulmonary diseases. However, in spite of improved surgical techniques, donor organ preservation solutions and immunosuppression regimes, chronic allograft rejection (CR), is a severe complication in the form of obliterative bronchiolitis (BO) and vasculopathy and limits longterm allograft survival. Multiple factors seem to be responsible for the development of CR. Besides acute rejections (AR) and lymphocytic bronchiolitis, oxidative stress plays a central role in the development of CR. However, suitable therapeutic options are still lacking. Many animal experiments with molecular hydrogen (H2) therapy were already carried out in a variety of disease fields. However, studies about the treatment of CR after LTx with H2 are still missing. Scavenging of free radicals by molecular hydrogen may act preventively or therapeutically. The aim of this study is to investigate the efficency of H2 as a therapeutical option of CR after experimental LTx.In a one-sided, orthotopic lung transplant model in rats (F344 in WKY) four study groups are designed to investigate the treatment of CR by means of H2. In this animal model, H2 should be used inhalatively (2% in a room air chamber) in addition to H2-enriched drinking water as well as via an intraperitoneal injection with H2-enriched physiological saline solution.The first group is based on the effect of H2 on CR alone. In two other groups, based on the current clinical situation to treat the CR after LTx, immunosuppressants (mycophenolate mofetil and everolimus) are used as a combination therapy with H2. Since it is known that the combination of various receptor tyrosine kinase inhibitors (RTK-I) reduced CR in animal experiments, the final study group is a combination of RTK Is with molecular H2. In addition to the question of the treatment of the CR by means of H2 after experimental LTx, this study will continue to contribute to the clarification of the pathological mechanism of the CR after LTx.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
气体信号分子硫化氢对颈动脉窦压力反射感受器的调节作用及机制
-
批准号:81100181
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:廖莹
-
依托单位:
气体信号分子硫化氢对腰椎间盘髓核细胞凋亡影响的实验研究
-
批准号:81071504
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:李淳德
-
依托单位:
硫化氢通过核转录因子-kB信号途径调节高血压大鼠血管平滑肌细胞增殖的研究
-
批准号:81070212
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2010
-
负责人:金红芳
-
依托单位:
水合物储存氢气的应用基础研究
-
批准号:50806050
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2008
-
负责人:谢应明
-
依托单位:
内源性硫化氢调控高血压血管基质重塑的研究
-
批准号:30801251
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2008
-
负责人:金红芳
-
依托单位: